Fertility and Family Building After Cancer: What to Ask, and When
Gonadotoxic exposures, ovarian reserve testing, premature ovarian insufficiency, and the conversations that too often happen years later than they should.
The fertility conversation is supposed to happen before treatment. Often it does not happen at all, and the question arrives years later with fewer options than it would have had. Here is what to ask, what the tests actually tell you, and what remains possible after the fact.
Which exposures matter most
Alkylating agents, particularly cyclophosphamide at cumulative doses, are the classic driver of premature ovarian insufficiency and of impaired spermatogenesis. Total-body irradiation and transplant conditioning sit at the high end of risk.
Pelvic and abdominal radiation affects both gonadal function and, in people with a uterus, the uterine capacity to carry a pregnancy. Cranial radiation can disrupt the pituitary axis, producing an entirely separate hormonal cause with the same downstream effect.
Age at treatment matters as much as dose. The same regimen has very different consequences at fifteen and at thirty-eight.
What the tests do and do not say
Anti-Mullerian hormone and antral follicle count describe present ovarian reserve. They are useful for planning and for counseling, and they are poor at predicting whether a specific person will conceive naturally in a given year.
Semen analysis after treatment can be normal, impaired, or absent, and can recover over years. A single result during or soon after treatment is not a final answer.
Premature ovarian insufficiency is a diagnosis with consequences beyond fertility: bone loss, cardiovascular risk, and vasomotor symptoms all follow, and each has its own management.
Options after treatment has ended
Referral to reproductive endocrinology is appropriate at any point, not only before treatment. Oocyte, embryo, and sperm cryopreservation remain available where function persists, and donor gametes, gestational carriers, and adoption are all part of the same conversation rather than a fallback.
Ask directly about the hormonal consequences of ovarian insufficiency and whether hormone therapy is appropriate for you. In some cancers it is; in others it is not, and the answer belongs to your oncology team.
Financial support exists. Several nonprofit programs specifically fund fertility preservation and treatment for people with a cancer history, and eligibility is often broader than people assume.
Frequently asked questions
- Nobody discussed fertility before my treatment. Is it too late?
- Not necessarily. Options narrow over time but rarely close entirely, and the hormonal consequences of impaired gonadal function are worth addressing regardless of whether you want children.
- Does a normal period mean my fertility is unaffected?
- No. Cycles can continue while ovarian reserve is substantially reduced, and insufficiency can develop years after treatment ends.
- Should this be in my transition-of-care plan?
- Yes. Gonadotoxic exposure, current reproductive status, and any preserved material belong in the plan so the next clinician does not have to reconstruct it.